Attached files
| file | filename |
|---|---|
| EX-32 - EX-32 - Eidos Therapeutics, Inc. | eidx-ex32_13.htm |
| EX-31 - EX-31 - Eidos Therapeutics, Inc. | eidx-ex31_8.htm |
| EX-4.5 - EX-4.5 - Eidos Therapeutics, Inc. | eidx-ex45_957.htm |
| 10-K - 10-K - Eidos Therapeutics, Inc. | eidx-10k_20191231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
|
|
• |
Registration Statement (Form S-8 No. 333-225798) pertaining to the Amended and Restated 2016 Equity Incentive Plan, 2018 Stock Option and Incentive Plan, and 2018 Employee Stock Purchase Plan of Eidos Therapeutics, Inc., |
|
|
• |
Registration Statement (Form S-8 No. 333-233000) pertaining to the Amended and Restated 2018 Stock Option and Incentive Plan of Eidos Therapeutics, Inc., and |
|
|
• |
Registration Statement (Form S-3/A No. 333-232999) of Eidos Therapeutics, Inc. |
of our report dated February 26, 2020, with respect to the financial statements of Eidos Therapeutics, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2019.
/s/ Ernst & Young LLP
San Francisco, California
February 26, 2020